Chemomab Therapeutics (CMMB) Change in Receivables (2018 - 2019)
Chemomab Therapeutics posted quarterly Change in Receivables of -$3.8 million for Q4 2019, down 163.99% year-on-year from $5.9 million in Q4 2018, and down 977.49% on a QoQ basis from -$351000.0 in Q3 2019.
Chemomab Therapeutics (CMMB) has 2 years of Change in Receivables data on file, last reported at -$3.8 million in Q4 2019.
- For the quarter ending Q4 2019, Change in Receivables fell 163.99% year-over-year to -$3.8 million; the trailing twelve-month figure through Dec 2019 stood at -$724000.0 (changed N/A YoY), and the FY2019 full-year result was -$2.3 million, down 165.93% from the prior year.
- Change in Receivables for Q4 2019 stood at -$3.8 million, down from -$351000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $5.9 million in Q4 2018 and bottomed at -$3.8 million in Q4 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -3.78 Mn |
| Dec 31, 2019 | -3.78 Mn |
| Sep 30, 2019 | -351,000.00 |
| Sep 30, 2019 | -351,000.00 |
| Dec 31, 2018 | 5.91 Mn |
| Dec 31, 2018 | 5.91 Mn |
| Sep 30, 2018 | -2.50 Mn |
| Sep 30, 2018 | -2.50 Mn |